Short Selling Report: Trust in Ophthalmic New Drug Leads to Over 2% Increase

Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) closed at $67.05 on July 6, up 2.46% on the Nasdaq, bringing its market capitalization to approximately $2.88 billion (₩3.9 trillion). In a single trading day, its market cap grew by roughly $73 million (₩100 billion), with trading volume totaling about 1.095 million shares.

At its recent annual meeting, the company passed board-governance and oversight proposals, reinforcing its corporate governance framework. Wall Street analysts continue to hold a “Moderate Buy” consensus rating with an average price target in the mid-$90s. However, a July 1 report from short-seller Culper Research, which raised concerns over the structure of the company’s patient-support program expenditures, has been cited as a factor driving short-term volatility. (pricetargets.com)

Tarsus Pharmaceuticals is a biotech firm specializing in ophthalmic diseases. It is commercializing XDEMVY™ (lotilaner ophthalmic solution 0.25%), the first and only FDA-approved therapy in the U.S. for Demodex blepharitis, and is growing its revenues accordingly. The company projects peak sales of more than $2 billion (₩2.7 trillion) for XDEMVY and is accelerating efforts to pursue additional indications and expand its pipeline in areas of unmet need in ophthalmology. (ir.tarsusrx.com)